Akebia Therapeutics | AKBA - 资产



金融业
股票价格
USD
资产
USD 376.57M
现金及等价物
USD 184.84M
销售成本
USD 10.34M
流动资产
USD 252.96M
流动负债
USD 162.94M
债务
USD 46.51M
股息收益率
0
EBIT
USD -5.45M
EBITDA
USD 14.03M
员工
167
EPS每股收益
USD -0.04
股本和储备
USD 32.61M
销售毛利
USD 47.28M
债务利息支出
4.83M
贷款资金
USD 48.25M
市值
USD 316M
净收入
USD -12.24M
营业费用
USD 63.08M
营业利润
USD -5.45M
普通股股本
USD 265.43M
PE价格收益
1.63K
税前利润
USD -11.24M
销售收入
USD 57.62M
销售和管理费用
USD 23.53M
股票
USD 15.61M
贸易债权人
USD 21.19M
应收帐款人
USD 47.03M


资产 更改 日
Acadia Pharmaceuticals USD 1.56B 233.42M 2025-12
Agios Pharmaceuticals USD 1.18B 112.24M 2026-03
Akebia Therapeutics USD 376.56M 12.41M 2025-12
Alnylam Pharmaceuticals USD 5.13B 163.22M 2026-03
Amgen USD 92.5B 1.92B 2026-03
Ardelyx USD 504.51M 2.9M 2026-03
Astellas Pharma JPY 3.57T 36.87B 2026-03
AstraZeneca USD 114.02B 59M 2026-03
Bayer EUR 104.54B 331M 2025-12
BioMarin Pharmaceutical USD 8.59B 996.99M 2026-03
Celltrion KRW 21.08T 530.63B 2025-09
Cspc Pharmaceutical CNY 46.7B 695.56M 2025-12
Deva Holding AS TRY 12.93B 1.83B 2023-09
Dianthus Therapeutics USD 1.25B 715.96M 2026-03
Exelixis USD 2.84B 20.87M 2025-12
Fresenius Medical Care EUR 31B 115.33M 2025-12
GlaxoSmithKline GBP 62.87B 1.75B 2026-03
Ionis Pharmaceuticals USD 3.45B 74M 2026-03
Ironwood Pharmaceuticals USD 396.06M 53.12M 2025-09
J&J USD 200.89B 1.68B 2026-03
Kangmei Pharma CNY 13.68B 38.19M 2025-09
Karyopharm Therapeutics USD 108.42M 12.18M 2025-12
Knight Therapeutics CAD 1.05B 2.28M 2025-12
Laboratorios Farma EUR 799.88M 99.95M 2023-12
Lexicon Pharmaceuticals USD 184.99M 20.94M 2025-12
Malin Corporation EUR 198.5M 70.1M 2024-12
Medical Developments International AUD 63.57M 2.83M 2025-12
Moderna USD 11.49B 850M 2026-03
Nektar Therapeutics USD 280.41M 20.94M 2025-12
Neuren Pharmaceuticals AUD 342.86M 11.61M 2025-12
Organigram Holdings CAD 530.67M 31.54M 2025-12
Ovoca Bio EUR 1.66M 9.75M 2025-06
Pharma Mar EUR 385.26M 9.82M 2026-03
Prothena USD 326.8M 25.82M 2025-12
PTC Therapeutics USD 2.9B 255.07M 2025-12
Qiagen NV USD 6.3B 257.54M 2025-12
Regeneron Pharmaceuticals USD 40.87B 310.1M 2026-03
Roche Holding CHF 100.7B 5.94B 2025-12
Sanofi EUR 128.02B 1.22B 2026-03
Sarepta Therapeutics USD 3.35B 143.73M 2025-12
Sartorius EUR 9.87B 154.9M 2026-03
Sino Biopharmaceutical CNY 74.89B 9.49B 2025-06
Tectonic Therapeutic USD 261.04M 15.96M 2025-12
Tilray USD 2.1B 15.95M 2025-09
Vanda Pharmaceuticals USD 488.95M 112.19M 2025-12
Zealand Pharma A/S 15.95B 848.45M 2025-12
Zz Pientze Pharmaceu CNY 18.38B 905.93M 2026-03